ARTICLE | Company News
Crucell, Dynavax deal
April 3, 2006 7:00 AM UTC
DVAX will acquire CRXL's Rhein Biotech GmbH subsidiary (Duesseldorf, Germany) for $12 million in cash. Rhein produces an HBV surface antigen that is used in DVAX's Heplisav HBV vaccine. DVAX said th...